Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
CERo Therapeutics Holdings, Inc. Common Stock (CERO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/02/2025: CERO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $
1 Year Target Price $
| 0 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -34.99% | Avg. Invested days 60 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/02/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 4.79M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta -0.44 | 52 Weeks Range 6.71 - 896.00 | Updated Date 05/15/2025 |
52 Weeks Range 6.71 - 896.00 | Updated Date 05/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.19 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -45.28% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 12726648 | Price to Sales(TTM) - |
Enterprise Value 12726648 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 51353500 | Shares Floating 46458656 |
Shares Outstanding 51353500 | Shares Floating 46458656 | ||
Percent Insiders 12.54 | Percent Institutions 9.05 |
Analyst Ratings
Rating 3.5 | Target Price - | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
CERo Therapeutics Holdings, Inc. Common Stock
Company Overview
History and Background
CERo Therapeutics Holdings, Inc. is a biopharmaceutical company focused on developing novel immunotherapies for cancer. It was founded to leverage proprietary technologies to engineer cell-based therapies.
Core Business Areas
- Cell Therapy Development: Focuses on developing engineered cell-based immunotherapies for various cancers.
Leadership and Structure
Details about leadership team (CEO, CFO, etc.) and organizational structure are generally available on the company's investor relations page or through SEC filings.
Top Products and Market Share
Key Offerings
- CERo-101 (example): A hypothetical engineered cell therapy candidate in preclinical/clinical development for solid tumors. Market share is currently 0% as it is not yet approved. Competitors include companies developing CAR-T therapies and other cell-based immunotherapies.
Market Dynamics
Industry Overview
The biopharmaceutical industry, particularly the immunotherapy sector, is experiencing significant growth. Advances in cell engineering and a deeper understanding of cancer immunology are driving innovation.
Positioning
CERo Therapeutics is positioned as a developer of novel cell-based cancer immunotherapies. Competitive advantages depend on proprietary technology and clinical trial success.
Total Addressable Market (TAM)
The TAM for cancer immunotherapies is estimated to be in the tens of billions of dollars annually and expected to grow. CERo Therapeutics is positioned to capture a segment of this market if its therapies are successful.
Upturn SWOT Analysis
Strengths
- Proprietary technology platform
- Experienced management team
- Potential for breakthrough therapies
Weaknesses
- Early stage development
- High R&D costs
- Dependence on funding
Opportunities
- Expanding immunotherapy market
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results
Threats
- Regulatory hurdles
- Competition from established players
- Clinical trial failures
Competitors and Market Share
Key Competitors
- BMY
- MRK
- GILD
- JNJ
Competitive Landscape
CERo Therapeutics faces competition from established pharmaceutical companies with larger R&D budgets and approved products. Success depends on differentiation and clinical efficacy.
Growth Trajectory and Initiatives
Historical Growth: Analyze stock charts, revenue growth, and clinical progress over the past years.
Future Projections: Gather analyst reports regarding revenue growth and market potential.
Recent Initiatives: Strategic partnerships, acquisitions, clinical trial progress.
Summary
CERo Therapeutics is an early-stage biotech company with potential in the cancer immunotherapy market. Its proprietary technology and experienced team are strengths, but high R&D costs and competition pose challenges. Positive clinical trial results and strategic partnerships will be crucial for future success. The company needs to closely monitor its cash runway and navigate the regulatory landscape carefully.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC filings
- Company website
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on individual circumstances and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About CERo Therapeutics Holdings, Inc. Common Stock
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2024-02-15 | CEO & Chair Mr. Christopher B. Ehrlich M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 8 | Website https://www.cero.bio |
Full time employees 8 | Website https://www.cero.bio | ||
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.